- ETST will investigate combination drugs that combine a mineral element with full spectrum cannabinoid industrial hemp oil; it anticipates completion of white paper studies in early 2019, with clinical trials to follow
- Goal is to produce both an OTC nutraceutical product and a cannabinoid companion generic drug to fight the epidemic of opioid dependency
- Foundations Wellness Center reports that two million Americans are now addicted to opioids
Earth Science Tech, Inc. (OTC: ETST) has set 2019 as the crucial year when the company anticipates completion of white paper studies and the start of human clinical trials to investigate the synergies of drugs that are intended to treat opioid dependency. It intends to test the effectiveness of combination drugs that contain a mineral element and full spectrum cannabinoid industrial hemp oil (http://ibn.fm/cL4Q0).
The clinical trials are expected to commence in 2019 or later. The goal is to produce an over-the-counter (OTC) treatment drug and a cannabinoid companion generic drug to battle opioid dependency. The Foundations Wellness Center reported that two million Americans were addicted to opioids in 2015, the most recent full year for which those statistics are currently available (http://ibn.fm/pyT1D).
The trials are likely to investigate the synergies between mineral elements and cannabinoid industrial hemp oil for use as a treatment for opioid dependency. ETST could then be positioned to bring new products to the marketplace. Per company reports, one drug could be designed to reduce the cravings of opioid addicts and the other, a generic, could make the treatment more effective and reduce the danger of side effects.
Addiction can lead to death from opioids. The Washington Post quotes two specialists as saying that the final death count relating to opioid addiction in 2017 could reach 50,000, higher than the number of AIDS deaths at the peak of that epidemic (http://ibn.fm/iSbs6).
ETST is a biotech company focused on the cannabinoid, pharmaceutical and nutraceutical markets, as well as conducting R&D for medical devices. It is a company that holds several operational subsidiaries, including Earth Science Pharmaceutical, Inc.; Cannabis Therapeutics, Inc.; and KannaBidioiD, Inc. In addition, the company holds a Montreal-based subsidiary, Canna Inno Laboratories, Inc., providing access to Canadian grants.
For more information, visit the company’s website at www.EarthScienceTech.com
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com